Clinical trial design in schizophrenia: implications for clinical decisions

Current Opinion in Psychiatry
Frank-Gerald Pajonk

Abstract

Results from clinical trials do not necessarily provide information for decisions in clinical practice. This review aims to present strengths and limitations of different methodological types of clinical trials and to offer an overview of how knowledge from clinical trails can be distilled for clinical practice. Selected key questions in the treatment of schizophrenia are presented, with a focus on the possibilities and restrictions of translating trial results into real-world practice. Randomized controlled trials are the gold standard for proving efficacy of a diagnostic or therapeutic procedure. They have a high degree of internal validity and a clear-cut message when conducted to good-quality standards but suffer from a lack of generalizability (external validity). Effectiveness studies evaluate effects of treatments under conditions approximating usual care. They may include patient-centred outcomes or health economic evaluations. According to the type of trial, specific problems arise in the interpretation of results. Typical examples are given for the treatment of acute exacerbations of schizophrenia, for relapse prevention and for the treatment of cognitive impairment. Clinical decisions have to be made upon the best kn...Continue Reading

References

May 1, 1994·Drugs·J M DavisL ] Metalon L [corrected to Matalon
Feb 1, 1994·Archives of General Psychiatry·A J SaykinR C Gur
Jul 23, 1998·Neuropsychology·R W Heinrichs, K K Zakzanis
Oct 31, 1998·BMJ : British Medical Journal·B Thornley, C Adams
Aug 6, 1999·Archives of General Psychiatry·S MohamedN Andreasen
Nov 30, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·R L Binder, D E McNiel
Jun 5, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·M V Seeman
Oct 3, 2001·The British Journal of Psychiatry : the Journal of Mental Science·C E AdamsA S David
Apr 12, 2002·Acta Psychiatrica Scandinavica·S GilbodyC Adams
Apr 23, 2002·The Journal of Mental Health Policy and Economics·Anthony F. Lehman
Jul 18, 2002·Epidemiologic Reviews·Jeremy Sugarman
Oct 3, 2002·The Journal of Nervous and Mental Disease·Daniel J Safer
Dec 31, 2002·Schizophrenia Research·Rajaprabhakaran RajarethinamJohn DeQuardo
Apr 29, 2003·The Journal of Clinical Psychiatry·Martina HummerW Wolfgang Fleischhacker
Jun 5, 2003·The Australian and New Zealand Journal of Psychiatry·Richard PorterRoger T Mulder
Jun 5, 2003·The Australian and New Zealand Journal of Psychiatry·Roger T MulderRichard Porter
Aug 2, 2003·Schizophrenia Research·Patrick W CorriganGregory A Toombs
Dec 3, 2003·The British Journal of Psychiatry : the Journal of Mental Science·C Bruce BakerScott W Woods
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank-Gerald Pajonk
Dec 24, 2003·BMC Medical Research Methodology·Marshall GodwinRachelle Seguin
Dec 31, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Gary R BondHaiyi Xie
Jan 8, 2004·Journal of Clinical Psychopharmacology·Tim LambertRobert R Conley
Jan 8, 2004·Seminars in Thoracic and Cardiovascular Surgery·Randi Zlotnik-Shaul, Martin F McKneally
Feb 12, 2004·The Medical Clinics of North America·Kevin C Abbott, George L Bakris
Feb 12, 2004·CNS Drugs·Susan M Cheer, Antona J Wagstaff
Jul 20, 2004·Drugs·Tracy Swainston Harrison, Caroline M Perry
Jul 30, 2004·Current Pharmaceutical Design·J AnanthB Hara
Nov 4, 2004·CNS Drugs·Kate McKeage, Greg L Plosker
Nov 19, 2004·European Archives of Psychiatry and Clinical Neuroscience·M RiedelH-J Möller
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew D Siderowf
May 3, 2005·The American Journal of Psychiatry·John S MarchRanga Krishnan
May 27, 2005·Drugs·John Battaglia
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Hans-Jürgen Möller

❮ Previous
Next ❯

Citations

May 11, 2010·Psychiatry Research·Johannes HamannFrank-Gerald Pajonk
Jul 14, 2006·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·James H HellerPriya S Kishnani
Feb 26, 2010·The Australian and New Zealand Journal of Psychiatry·Stanley V CattsRussell W Evans
Dec 19, 2013·PloS One·Sarah HardoonDavid P J Osborn
Dec 5, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Duerten KudlaDieter Naber
Nov 25, 2016·The Cochrane Database of Systematic Reviews·Yijun WangStefan Leucht

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.